

ACSAP 2023 Book 1 (*Cardiology Care*)

Release date: March 15, 2023

BCACP test deadline: 11:59 p.m. (Central) on September 15, 2023.

ACPE test deadline: 11:59 p.m. (Central) on March 15, 2026.



Continuing Pharmacy Education Credit: The American College of Clinical Pharmacy

and the American Society of Health-System Pharmacists are accredited by the Accreditation Council for Pharmacy Education (ACPE) as providers of continuing pharmacy education (CPE).

ACSAP Target Audience: The target audience for ACSAP 2023 Book 1 (*Cardiology Care*) is board-certified and advanced level ambulatory care clinical pharmacists who provide care for patients with or at risk of conditions and disorders related to cardiology.

Module 1 (4.0 CPE) Cardiology Care I

UAN: 0217-9999-23-022-H01-P

Chapter: Updates in the Management of Heart Failure

Learning Objectives

1. Evaluate key recommendations and recent updates in the national guidelines in the treatment of heart failure (HF).
2. Analyze drug therapies according to the revised terminology and categories of HF.
3. Design practical strategies to optimize individualized guideline-directed medical therapies.

Chapter: Dyslipidemia Management Updates

Learning Objectives

1. Assess low-density lipoprotein (LDL)-based treatment recommendations and targets based on common clinical dilemmas.
2. Evaluate the role and place in therapy of bempedoic acid, inclisiran, and evinacumab in the treatment of dyslipidemia.
3. Apply appropriate management strategies for lowering LDL in statin-intolerant patients.

Module 2 (4.5 CPE) Cardiology Care II

UAN: 0217-9999-23-023-H01-P

Chapter: DOAC Use in Special Populations

Learning Objectives

1. Account for the classification of special populations for direct oral anticoagulant (DOAC) use.
2. Analyze the emerging evidence for DOAC use in specific special populations.
3. Apply evidence and societal guidelines to guide the use of DOACs in specific patient populations.

4. Evaluate the degree of uncertainty of DOAC use in specific patient populations.

Chapter: Updates in Cardio-Oncology

Learning Objectives

1. Given a patient on anticancer therapy, evaluate the patient's risk of developing vascular toxicities, establish treatment goals, and construct a therapeutic plan.
2. Devise a risk mitigation and treatment strategy for patients on anticancer therapy at risk of developing heart failure.
3. Evaluate which patients on anticancer therapy are at risk of developing atrial fibrillation and design a plan for risk management and monitoring.
4. For patients on anticancer therapy, assess individual risk of developing QTc prolongation and develop a plan for prevention, treatment, and surveillance.
5. Assess a patient's risk of developing myocarditis and construct a monitoring and treatment plan.

Module 3 (4.5 CPE) Cardiology Care III

UAN: 0217-9999-23-024-H01-P

Chapter: Stable Ischemic Heart Disease Management Updates

Learning Objectives

1. Distinguish between drug therapy recommendations for cardiovascular (CV) risk reduction and symptomatic relief of symptoms in patients with stable ischemic heart disease (SIHD) based on current guidelines.
2. Develop an evidence-based pharmacologic regimen for patients with SIHD for both CV risk reduction and symptomatic relief of symptoms.
3. Analyze the optimal use of antithrombotic therapy for patients with SIHD.
4. Assess the optimal use of omega-3 fatty acids in patients with SIHD and hypertriglyceridemia.
5. Evaluate the impact of colchicine on CV risk reduction in patients with SIHD.

Chapter: Pharmacogenomics and Cardiovascular Disease

Learning Objectives

1. Evaluate the clinical use of pharmacogenomic testing for cardiovascular medications to guide therapeutic recommendations.
2. Assess genotype results and other raw pharmacogenomic data to determine actionable prescribing using pharmacogenetic guidelines, resources, and knowledge bases.
3. Develop a therapeutic plan for cardiovascular health management incorporating patient-specific clinical factors and pharmacogenomic test results.
4. Evaluate the supporting evidence, clinical validity, and clinical use of pharmacogenetic testing for cardiovascular medications with no currently available pharmacogenetic prescribing recommendations.

Module 4 (4.5 CPE) Cardiology Care IV

UAN: 0217-9999-23-025-H01-P

Interactive Case: Role of Colchicine in Secondary Prevention of CVD

Learning Objectives

1. Discover the role of inflammation in the mediation of atherosclerotic disease progression and ultimate events.
2. Assess historic strategies targeting inflammation and outcomes related to cardiovascular disease (CVD).
3. Analyze the role of colchicine therapy with relation to CVD risk reduction.
4. Devise a strategy for integrating colchicine into treatment plans for CV risk reduction.

Interactive Case: Lower Extremity Peripheral Artery Disease

Learning Objectives

1. Justify the need for atherosclerotic risk reduction strategies in a patient with lower extremity peripheral artery disease (LE-PAD).
2. Detect whether a patient with LE-PAD has symptoms.
3. Evaluate the risk-benefit of antiplatelet therapy for a patient with asymptomatic LE-PAD.
4. Design an antithrombotic treatment regimen for a patient with symptomatic LE-PAD.
5. Develop an antithrombotic treatment regimen for a patient who underwent revascularization for LE-PAD.

Interactive Case: Telehealth and Self-Monitoring of Blood Pressure

Learning Objectives

1. Evaluate requirements for implementing, conducting, and billing for telehealth services.
2. Assess a patient's home blood pressure monitor and technique.
3. Evaluate a patient for primary, resistant, or secondary hypertension.
4. Analyze a patient's home readings, laboratory values, and medical history and recommend appropriate medication.